differentiated antibiotics

Cempra to Participate in Jefferies 2015 Antibiotic Summit Investor Conference

CHAPEL HILL, N.C., March 16, 2015 -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today announced it will be participating in the Jefferies 2015 Antibiotic Summit meeting for investors. Prabhavathi Fernandes, Ph.D., chief executive officer and David Moore, chief commercial officer of Cempra, will provide a company overview and update on the company's clinical programs. The summit will be held on Wednesday, March 18, 2015 in New York. 

 

Cempra Reports Fourth Quarter and Full Year 2014 Financial Results and Provides Corporate Update

CHAPEL HILL, N.C., Feb. 25, 2015 -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today reported financial results for the quarter and year ended December 31, 2014 and provided an update on recent corporate developments. The company will host a webcast and conference call today at 4:30 p.m. EST.